• Mahil Rao, Patrick W McGonagill, Scott Brackenridge, Kenneth E Remy, Charles C Caldwell, Richard S Hotchkiss, Lyle L Moldawer, Thomas S Griffith, and Vladimir P Badovinac.
• Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa, 52242, USA.
• Shock. 2024 Nov 20.

AbstractSepsis remains a significant cause of morbidity and mortality worldwide. While many more patients are surviving the acute event, a substantial number enter a state of persistent inflammation and immunosuppression, rendering them more vulnerable to infections. Modulating the host immune response has been a focus of sepsis research for the past fifty years, yet novel therapies have been few and far between. While many septic patients have similar clinical phenotypes, pathways affected by the septic event differ not only between individuals but also within an individual over the course of illness. These differences ultimately impact overall immune function and response to treatment. Defining the immune state - or endotype - of an individual is critical to understanding which patients will respond to a particular therapy. In this review, we highlight current approaches to define the immune endotype and propose that these technologies may be used to "pre-screen" individuals to determine which therapies are most likely to be beneficial.Copyright © 2024 by the Shock Society.

15 keywords...

hide…